MSS mCRC tumors generally have fewer infiltrative CD8+ T-cell populations than MSI-H tumors [22], and immuno-oncological approaches with checkpoint inhibition alone may be insufficient for patients with limited tumor immune cell infiltration. The gene discussed is CD8A; the disease is neoplasm.